

Tables

1.1	Estimated 2004 US sales losses due to copyright piracy in 52 selected countries	10
6.1	A timeline for India's patent law	99
6.2	Number of companies in the Indian pharmaceutical industry	100
6.3	Characteristics of the Indian pharmaceutical industry	103
6.4	India's ten largest pharmaceutical companies by market capitalization in 2004	103
6.5	India's ten largest pharmaceutical companies by sales in 2004	104
6.6	Strengths and opportunities for the Indian pharmaceutical industry	104
6.7	India's top-ten pharmaceutical companies' R&D expenditures	105
6.8	India's domestic patent growth	108
6.9	Indian post-reform pharmaceutical patents	108
6.10	Pre- and post-reform patents for Indian pharmaceutical companies	109
6.11	Percentage of process-oriented patents in India's pharmaceutical companies	110
13.1	Evolution of average IPR index scores for developing countries, 1990–2000	243
13.2	Correlation of selected institutional indicators: CEPII <i>Institutional Profiles</i> database (2001) versus the 'Park <i>et al.</i> ' Enforcement and Patent Indices (2000)	246
13.3	The relationship between merchandise import flows and patent protection, 1990–2005	249
13.4	Estimates of relationship between inward FDI stock and patent protection, 1990–2005	250
13.5	Estimates of relationship between outward US FDI stock in developing countries and patent protection, by industry, 1990–2005	250
13.6	Royalty and licensing fees for the use of intangible assets, received from abroad by US parent firms	253
13.7	Intellectual property rights: royalty and licensing fees from unaffiliated sources, firm level	254
13.8	Intellectual property rights and US royalty and licensing fees relative to trade and foreign direct investment	255
13.9	The relationship between patent reform and high-tech licensing transactions in developing countries	257